# Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer

> **NCT07314619** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 30 (estimated)

## Conditions studied

- Platinum-resistant Recurrent Ovarian Cancer (PROC)

## Interventions

- **DRUG:** Sacituzumab Tirumotecan Combined with Bevacizumab

## Key facts

- **NCT ID:** NCT07314619
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-30
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07314619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07314619, "Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07314619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*